With Zejula’s third local approval, Zai ready for mainland China launch

China’s approval of Zejula gives Zai Lab its first approval in mainland China and allows the company to start marketing the PARP inhibitor in the largest of the three markets in which it holds rights. The approval was one of three announced by the National Medical Products Administration on Friday.

NMPA approved Zejula niraparib as maintenance therapy for adults with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy, regardless of BRCA mutation status...